The efficacy of RNA-seq-based endometrial receptivity test (rsERT) in guiding personalized embryo transfer in women with polycystic ovarian syndrome without recurrent implantation failure: a randomized controlled trial.

IF 2.7 3区医学 Q2 GENETICS & HEREDITY

Journal of Assisted Reproduction and Genetics Pub Date : 2025-09-13 DOI:10.1007/s10815-025-03627-x

Jingjing Chen, Jianjuan Zhao, Qin Hu, Jing Fu, Jing Zhao, Qiong Zhang, Bin Xu, Hui Li, Yanping Li

{"title":"The efficacy of RNA-seq-based endometrial receptivity test (rsERT) in guiding personalized embryo transfer in women with polycystic ovarian syndrome without recurrent implantation failure: a randomized controlled trial.","authors":"Jingjing Chen, Jianjuan Zhao, Qin Hu, Jing Fu, Jing Zhao, Qiong Zhang, Bin Xu, Hui Li, Yanping Li","doi":"10.1007/s10815-025-03627-x","DOIUrl":null,"url":null,"abstract":"Purpose: To assess the effectiveness of personalized embryo transfer (pET) in enhancing intrauterine pregnancy rates in women with polycystic ovary syndrome (PCOS) without recurrent implantation failure (RIF).Methods: This single-center, open-label, randomized controlled trial was conducted at a university-affiliated assisted reproductive medical center between October 2022 and May 2024. Eligible participants were randomly assigned to either the pET arm guided by the RNA-seq-based endometrial receptivity test (rsERT) or the regular frozen embryo transfer (FET) arm. Clinical outcomes from the first embryo transfer cycles following the tests were tracked and compared between the groups.Results: A total of 121 patients were included and randomly assigned to either the FET arm (n = 60) or the pET arm (n = 61). Intention-to-treat analyses revealed no significant differences between the FET group and the pET group in terms of intrauterine pregnancy rate (61.2% vs. 60.0%, difference, - 1.2% [95% CI, - 20.2 to 17.9%], p = 0.901), embryo implantation rate (54.7% vs. 50.7%, difference, - 4.0% [95% CI, - 20.5 to 12.8%], p = 0.643), early miscarriage rate (3.3% vs. 6.7%, difference, 3.3% [95% CI, - 11.1 to 18.7%], p = 1.000), and ongoing pregnancy rate (59.2% vs. 56.0%, difference, - 3.2% [95% CI, - 22.3 to 16.2%], p = 0.749). Subgroup analyses of intrauterine pregnancy rates revealed no statistically significant differences between the groups, regardless of the analysis method used.Conclusions: Current evidence does not support the routine use of rsERT for personalized embryo transfer in PCOS patients without RIF. Further large-scale, well-designed clinical trials are needed.Trial registration: The trial was registered on the Chinese Clinical Trial Registry (registration no. ChiCTR2200064131, prospectively registered). Trial registration date: 2022-09-27.","PeriodicalId":15246,"journal":{"name":"Journal of Assisted Reproduction and Genetics","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Assisted Reproduction and Genetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10815-025-03627-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To assess the effectiveness of personalized embryo transfer (pET) in enhancing intrauterine pregnancy rates in women with polycystic ovary syndrome (PCOS) without recurrent implantation failure (RIF).

Methods: This single-center, open-label, randomized controlled trial was conducted at a university-affiliated assisted reproductive medical center between October 2022 and May 2024. Eligible participants were randomly assigned to either the pET arm guided by the RNA-seq-based endometrial receptivity test (rsERT) or the regular frozen embryo transfer (FET) arm. Clinical outcomes from the first embryo transfer cycles following the tests were tracked and compared between the groups.

Results: A total of 121 patients were included and randomly assigned to either the FET arm (n = 60) or the pET arm (n = 61). Intention-to-treat analyses revealed no significant differences between the FET group and the pET group in terms of intrauterine pregnancy rate (61.2% vs. 60.0%, difference, - 1.2% [95% CI, - 20.2 to 17.9%], p = 0.901), embryo implantation rate (54.7% vs. 50.7%, difference, - 4.0% [95% CI, - 20.5 to 12.8%], p = 0.643), early miscarriage rate (3.3% vs. 6.7%, difference, 3.3% [95% CI, - 11.1 to 18.7%], p = 1.000), and ongoing pregnancy rate (59.2% vs. 56.0%, difference, - 3.2% [95% CI, - 22.3 to 16.2%], p = 0.749). Subgroup analyses of intrauterine pregnancy rates revealed no statistically significant differences between the groups, regardless of the analysis method used.

Conclusions: Current evidence does not support the routine use of rsERT for personalized embryo transfer in PCOS patients without RIF. Further large-scale, well-designed clinical trials are needed.

Trial registration: The trial was registered on the Chinese Clinical Trial Registry (registration no. ChiCTR2200064131, prospectively registered). Trial registration date: 2022-09-27.

查看原文本刊更多论文

基于rna -seq的子宫内膜容受性试验（rsERT）指导无复发性着床失败的多囊卵巢综合征女性个体化胚胎移植的疗效：一项随机对照试验。

目的：探讨个体化胚胎移植（pET）对无复发性着床失败（RIF）的多囊卵巢综合征（PCOS）患者提高宫内妊娠率的效果。方法：该单中心、开放标签、随机对照试验于2022年10月至2024年5月在某大学附属辅助生殖医学中心进行。符合条件的参与者被随机分配到由基于rna序列的子宫内膜容受性试验（rsERT）指导的pET组或常规冷冻胚胎移植（FET）组。在测试后的第一个胚胎移植周期的临床结果被跟踪并在两组之间进行比较。结果：共纳入121例患者，并随机分配到FET组（n = 60）或pET组（n = 61）。意向治疗分析显示，FET组和pET组在宫内妊娠率（61.2%比60.0%，差异为- 1.2% [95% CI, - 20.2 ~ 17.9%], p = 0.901）、胚胎着床率（54.7%比50.7%，差异为- 4.0% [95% CI, - 20.5 ~ 12.8%], p = 0.643）、早期流产率（3.3%比6.7%，差异为3.3% [95% CI, - 11.1 ~ 18.7%], p = 1.000）和持续妊娠率（59.2%比56.0%,p = 1.000）方面无显著差异。差异,- 3.2%(95%可信区间,22.3 - 16.2%),p = 0.749)。子宫内妊娠率的亚组分析显示，无论采用何种分析方法，两组之间没有统计学上的显著差异。结论：目前的证据不支持在无RIF的PCOS患者中常规使用rsERT进行个性化胚胎移植。需要进一步的大规模、精心设计的临床试验。试验注册：试验已在中国临床试验注册中心注册(注册号：。ChiCTR2200064131，已前瞻性注册)。试验注册日期：2022-09-27。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Assisted Reproduction and Genetics 医学-妇产科学

CiteScore

5.70

自引率

9.70%

发文量

286

审稿时长

1 months

期刊介绍： The Journal of Assisted Reproduction and Genetics publishes cellular, molecular, genetic, and epigenetic discoveries advancing our understanding of the biology and underlying mechanisms from gametogenesis to offspring health. Special emphasis is placed on the practice and evolution of assisted reproduction technologies (ARTs) with reference to the diagnosis and management of diseases affecting fertility. Our goal is to educate our readership in the translation of basic and clinical discoveries made from human or relevant animal models to the safe and efficacious practice of human ARTs. The scientific rigor and ethical standards embraced by the JARG editorial team ensures a broad international base of expertise guiding the marriage of contemporary clinical research paradigms with basic science discovery. JARG publishes original papers, minireviews, case reports, and opinion pieces often combined into special topic issues that will educate clinicians and scientists with interests in the mechanisms of human development that bear on the treatment of infertility and emerging innovations in human ARTs. The guiding principles of male and female reproductive health impacting pre- and post-conceptional viability and developmental potential are emphasized within the purview of human reproductive health in current and future generations of our species. The journal is published in cooperation with the American Society for Reproductive Medicine, an organization of more than 8,000 physicians, researchers, nurses, technicians and other professionals dedicated to advancing knowledge and expertise in reproductive biology.